Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA (DARE-VVA1)

  • STATUS
    Recruiting
  • days left to enroll
    85
  • participants needed
    40
  • sponsor
    Daré Bioscience, Inc.
Updated on 26 May 2022
Accepts healthy volunteers

Summary

The purpose of the study is to study the safety, PK and PD of Intravaginal Tamoxifen on postmenopausal women with vulvar vaginal atrophy.

Details
Condition Vulvar Atrophy
Treatment Placebo, tamoxifen
Clinical Study IdentifierNCT05378269
SponsorDaré Bioscience, Inc.
Last Modified on26 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

\. Women aged 40-75 (inclusive). 2. Postmenopausal women with a body mass index between 18 and 34 kg/m2, inclusive. 3. Postmenopausal, defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels > 40 mIU/mL or 6 weeks post-surgical bilateral oophorectomy. 4. Have moderate to severe VVA as determined by self-assessment of the following symptoms (as none, mild, moderate, or severe), with at least 1 symptom reported as moderate or severe: vaginal dryness; vaginal and/or vulvar irritation/itching; dysuria; vaginal pain with sexual activity (dyspareunia); vaginal bleeding associated with sexual activity (presence versus absence). 5. Women who currently have vaginal intercourse or other sexual activity (masturbation, etc.) at least once a month (with or without a partner), or who had intercourse or other sexual activity at least once a month in the past, but later decreased sexual activity due to excessive pain or vaginal dryness. Participants must be willing to engage in vaginal intercourse or other sexual activity (masturbation, etc.) at least 1 time between Days 49-56 of the clinical study. 6. Participants, upon pelvic examination with speculum examination, must have a normal-appearing vulva other than atrophic changes, normal-appearing cervix other than atrophic changes (i.e., cervical stenosis and/or flushness with the vaginal wall) and normal-appearing vagina (without erosions, ulcerations, scarring, or evidence of dermatoses) other than atrophic changes (loss of ruggae, mucosal pallor, mucosal dryness, mucosal petechiae). 7. Have an intact uterus and no prior history of endometrial ablation. 8. Vaginal cellular cytology with ≤ 5% superficial cells. 9. Vaginal pH > 5 at Screening Visit. 10. Endometrial thickness ≤ 4 mm on transvaginal ultrasound. 11. Current on all recommended screening and management requirements for cervical cancer. 12. Normal mammogram report within 2 years of screening. 13. Normal manual breast examination by investigator at baseline. 14. Baseline hematology, clinical chemistry, urinalysis, prothrombin time/partial thromboplastin time (PT/PTT) and viral serologies for human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B surface antigen (HBsAg) all within normal limits OR accepted by the investigator and medical monitor as not clinically significant. 15. Normal 12-lead electrocardiogram (ECG). 16. Able to read, understand, and provide written informed consent and applicable data protection authorization after the nature of the study has been fully explained, and must be willing to comply with all study requirements. 17. Willing and able to correctly and independently complete all study procedures

Exclusion Criteria

A history of or physical examination finding for any significant cardiovascular, renal, pulmonary, neurological and hepatic diseases preventing compliance with this study
A medical history of or use of anticoagulant drugs to treat or prevent coagulopathies, thrombophilia or thromboembolic disease (deep vein thrombosis, pulmonary or systemic embolism, stroke, or transient ischemic attack)
Uncontrolled hypertension (either systolic > 180 mmHg or diastolic > 105 mmHg), treatment with Class 1 antiarrhythmics or digitalis, history of congestive heart failure (New York Heart Association [NYHA] > Class I), or myocardial infarction within 12 months
Abnormal cervical screening test within 2 years of screening. Participant can have atypical squamous cells of undetermined significance if human papilloma virus-negative
History of or current endometrial pathology: hyperplasia, carcinoma and/or polyp (prior history of a benign endometrial polyp with no current evidence of polyp is acceptable)
A medical history of breast cancer within 5 years of screening. Participants with a history of breast cancer more than 5 years prior to screening are considered eligible if their disease was node-negative, nonmetastatic, and if all treatment with aromatase inhibitors (AIs) or SERMs was completed at least 6 months prior to screening
A medical history of malignant melanoma
Any cancer (except nonmelanomatous skin cancer) diagnosed less than 5 years prior to the Screening Visit
A medical history of undiagnosed vaginal bleeding
A known or suspected estrogen-dependent neoplasia
Previous radiation treatment to the pelvis
Women who have previously reported an unsatisfactory outcome from a vaginal hormone therapy for VVA
Known hypersensitivity to any ingredients in DARE-VVA1
Use of vaginal hormonal products (rings, creams, gels, tablets, capsules) within 4 weeks prior to Day 1
Use of transdermal estrogen or transdermal estrogen/progestin products within 4 weeks prior to Day 1
Use of oral estrogen and/or progestin therapy within 8 weeks prior to Day 1
Use of intrauterine progestin therapy within 8 weeks prior to Day 1
Use of progestin implants or estrogen-alone injectable drug therapy within 12 weeks prior to Day 1
Administration of estrogen pellet therapy or progestin injectable drug therapy within 6 months prior to Day 1
Use of thyroid hormone replacement therapy unless the participant is on a stable dose for > 6 months, and participant is euthyroid based on a normal, sensitive immunoassay for thyroid-stimulating hormone (TSH)
Use of SERMs or AIs within 6 months prior to screening
Use of anabolic or other steroids (including hormonal creams such as testosterone) within 4 weeks prior to Day 1
Use of corticosteroids, > 5 mg/day prednisone or equivalent, for more than 4 weeks within 4 weeks prior to Day 1
Participants with any self-reported active sexually transmitted disease and/or evidence of infection (including bacterial vaginosis) on vaginal examination by the investigator
Participants with a urinary tract infection during screening as assessed by urine dipstick test with abnormal test findings (any positive result for leukocytes AND any positive result for nitrites)
Presence of clinically significant uterine fibroids
Evidence of current alcohol or drug abuse in the past 60 days, including a positive result from the urine drugs of abuse or alcohol screen, or history of drug or alcohol dependence in the last 2 years, as assessed by the investigator. Alcohol abuse is defined as greater than 14 standard units/week for females, and drug abuse is defined as known psychiatric or substance abuse disorder that would interfere with participation with the requirements of this study, including current use of any illicit drugs. Use of medical cannabis is not exclusionary
Participation in any other investigational drug or device trial in which administration of an investigational study drug/device occurred within 30 days or placement of a non-drug eluting medical device within 15 days prior to the Screening Visit (Visit 1)
In the opinion of the investigator, participant has any disorder or finding that might interfere with the conduct of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note